Monica D. Mead

Nov 6, 2024 | nature.com | Adam S. Kittai |Antonio Gutierrez |Antonio Gutiérrez |Alejandro Martín García-Sancho |Monica D. Mead |Pere Barba | +2 more

The rationale for this project arises from some considerations. Clinical trials often use surrogate endpoints (response rates) rather than direct measurement of benefit (survivals) as primary objective of the study.

Aug 25, 2023 | onclive.com | Monica D. Mead

Monica D. Mead, MD, assistant clinical professor, medicine, Hematologic Malignancy, the University of California, Los Angeles (UCLA), UCLA Health, UCLA Jonsson Comprehensive Cancer Center, discusses the efficacy and safety differences between the second-generation BTK inhibitor zanubrutinib (Brukinsa) and the first-generation BTK inhibitor ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL).

Aug 24, 2023 | onclive.com | Monica D. Mead

Monica D. Mead, MD, assistant clinical professor, medicine, Hematologic Malignancy, the University of California, Los Angeles (UCLA), UCLA Health, UCLA Jonsson Comprehensive Cancer Center, discusses reasons for the declining use of the BTK inhibitor ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL). As ibrutinib was the first BTK inhibitor to gain FDA approval for patients with MCL, it was once the only BTK inhibitor in use in this population, Mead says.

Aug 23, 2023 | onclive.com | Monica D. Mead

Monica D. Mead, MD, assistant clinical professor of medicine, Department of Hematologic Malignancy, the University of California, Los Angeles (UCLA), UCLA Health, UCLA Jonsson Comprehensive Cancer Center, discusses the impact of key data on the role of ibrutinib (Imbruvica) in the treatment of mantle cell lymphoma (MCL).